US · Healthcare · Biotechnology
EPS came in at -0.93 against a street estimate of -0.82 — a miss of 13.4%.
Analysts rate Stoke Therapeutics Inc a strong buy (14 buy, 0 hold, 0 sell out of 14) with an average price target of $46.46.
CONFIDENT EMPEROR Phase III enrollment complete (162 patients, 0 discontinuations). Data readout Q3 2027 supports NDA filing Q1 2027. $420M cash runway to early 2028 launch. OLE data show durable seizure reduction and cognitive gains through 4 years. Q2 2026 U.S. is primary focus with 16,000-patient prevalence. Europe supports EMPEROR completion. Biogen handles ROW expansion. Analysts probed study powering (2–3 point Vineland delta vs. 8–11 observed), disease-modification label narrative (OLE data inclusion strategy), and commercial capacity (SPINRAZA precedent). Management emphasized 0% discontinuation dramatically improves secondary endpoint power, FDA pre-NDA meeting to align on OLE inclusion and SAP hierarchy, and site readiness via existing intrathecal infrastructure. 2026-08-03…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.11% |
| RTW INVESTMENTS, LLC | 8.72% |
| FMR Inc | 8.23% |
| Lynx1 Capital Management, LP | 6.26% |
| Redmile Group, LLC | 6.12% |
| Wellington Management Company LLP | 5.45% |
| Morgan Stanley - Brokerage Accounts | 5.31% |
| Baker Bros Advisors LP | 5.17% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 STOKE THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • New board member Alexander (Bo) Cumbo appointed September 23, 2026 • Initial stock option | 2026-09-25 |
| Quarterly report · Q2 2026 STOKE THERAPEUTICS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Equivalents: $110.0 million as of June 30, 2026 (up from $84.2 million Dec | 2026-08-03 |
| Company announcement · Q3 2026 STOKE THERAPEUTICS, INC. - 8-K FILING SUMMARY HEADLINE NUMBERS • Company filed prospectus supplement on August 3, 2026 for up to $200,000,000 in new | 2026-08-03 |
| Results announced · Q3 2026 STOKE THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $420.0 million (comprised of $354.3 million as of June 30, 20 | 2026-08-03 |
| Reg FD disclosure · Q2 2026 STOKE THERAPEUTICS, INC. – 8-K SUMMARY (June 30, 2026) HEADLINE NUMBERS • Phase 3 EMPEROR study enrollment complete: 162 patients enrolled across U. | 2026-06-30 |
| Shareholder vote results · Q2 2026 STOKE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 3, 2026 • Three Class I directors elected to three-ye | 2026-06-04 |
| Quarterly report · Q1 2026 STOKE THERAPEUTICS, INC. – 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash position: $155.7 million in cash and cash equivalents as of March 31, 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 STOKE THERAPEUTICS, INC. – PROXY STATEMENT SUMMARY --- CEO COMPENSATION AND CHANGE • Ian F. Smith's total compensation: Document does not specify e | 2026-04-22 |
Readable in the app.
| Announcement | Date |
|---|---|
| Lease agreement for new facility or production space Stoke Therapeutics filed an 8-K on January 27, 2026, disclosing a lease agreement. Item 2.03 of the filing references Item 1.01, which contains details about the lease arrangement. However, | 2026-01-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Stoke Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.